Case number 1:23-cv-01196
Bayer Pharma AG et al v. Cipla Ltd. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Dec 15, 2023 | 14 | STIPULATION and [Proposed] Order Regarding Consolidation and Schedule, by Bayer AG, Bayer Pharma AG, Janssen Pharmaceuticals, Inc.. (Fahnestock, Derek) Modified on 12/15/2023 (nms). (Entered: 12/15/2023) (3) |
| Dec 15, 2023 | 15 | SO ORDERED Granting (D.I.158 in 21-cv-314-RGA-LDH; D.I. 14 in 23-cv-1196-RGA; D.I. 202 in 21-md-3017-RGA-LDH) Stipulation and Order Regarding Consolidation and Schedule: Civil Action 23-1196-RGA is consolidated with Civil Action 21 314-RGA-JLH for all purposes, including for trial. All papers shall be filed in Civil Action 21-314-RGA-JLH (see Order for further details). Signed by Judge Richard G. Andrews on 12/15/2023. Associated Cases: 1:21-md-03017-RGA-LDH, 1:21-cv-00314-RGA-LDH, 1:23-cv-01196-RGA(nms) (Entered: 12/15/2023) (3) |
| Dec 14, 2023 | N/A | SO ORDERED, re (D.I. 201 in 21-md-3017-RGA-LDH; D.I. 13 in 23-cv-1196-RGA) STIPULATION Extending Time to Respond to Complaint to December 22, 2023. Signed by Judge Richard G. Andrews on 12/14/2023. Associated Cases: 1:21-md-03017-RGA-LDH, 1:23-cv-01196-RGA(nms) (Entered: 12/14/2023) (0) |
| Dec 13, 2023 | 13 | STIPULATION Extending Time to Respond to Complaint to December 22, 2023 - filed by Cipla Ltd., Cipla USA Inc., Invagen Pharmaceuticals, Inc.. (Ferraro, April) Modified on 12/14/2023 (nms). (Entered: 12/13/2023) (2) |
| Nov 21, 2023 | 12 | SO ORDERED Granting (D.I. 197 in 21-md-3017-RGA-LDH; D.I. 11 in 23-cv-1196-RGA) Stipulation and Proposed Order Joining Invagen Pharmaceuticals, Inc. (Invagen Pharmaceuticals, Inc. added). Signed by Judge Richard G. Andrews on 11/21/2023. Associated Cases: 1:21-md-03017-RGA-LDH, 1:23-cv-01196-RGA(nms) (Entered: 11/21/2023) (3) |
| Nov 20, 2023 | N/A | CORRECTING ENTRY: The stipulation filed at D.I. 11 on 11/17/2023, has been removed from the docket as its caption was deficient. This case is a member to MDL 21-3017-RGA-LDH, thereby requiring that it be captioned and filed in the MDL and the underlying civil action. Counsel is to correct the stipulation and refiled. (nms) (Entered: 11/20/2023) (0) |
| Nov 20, 2023 | 11 | STIPULATION and [Proposed] Order Joining Invagen Pharmaceuticals, Inc. by Cipla Ltd., Cipla USA Inc.. (Ferraro, April) (Entered: 11/20/2023) (3) |
| Nov 7, 2023 | 10 | STIPULATION TO EXTEND TIME for Defendants Cipla Ltd and Cipla USA Inc. to answer, move, or otherwise respond to the Complaint in this action (D.I. 1) to December 14, 2023 - filed by Bayer AG, Bayer Pharma AG, Janssen Pharmaceuticals, Inc.. (Fahnestock, Derek) (Entered: 11/07/2023) (2) |
| Nov 7, 2023 | N/A | SO ORDERED, re (D.I. 10 in 23-cv-1196-RGA; D.I. 196 in 21-md-3017-RGA-LDH) STIPULATION to Extend Time for Cipla Ltd and Cipla USA Inc. to answer, move, or otherwise respond to the Complaint in this action to December 14, 2023. Signed by Judge Richard G. Andrews on 11/7/2023. Associated Cases: 1:21-md-03017-RGA-LDH, 1:23-cv-01196-RGA(nms) (Entered: 11/07/2023) (0) |
| Oct 25, 2023 | N/A | Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (nms) (Entered: 10/25/2023) (0) |
| Oct 25, 2023 | 8 | SUMMONS Returned Executed by Bayer Pharma AG, Janssen Pharmaceuticals, Inc., Bayer AG.Cipla USA Inc. served on 10/24/2023, answer due 11/14/2023. (Fahnestock, Derek) (Entered: 10/25/2023) (2) |
| Oct 25, 2023 | 9 | AFFIDAVIT of Service for Summons, Complaint and related papers served on Cipla Ltd. on October 24, 2023, filed by Bayer AG, Bayer Pharma AG, Janssen Pharmaceuticals, Inc.. (Fahnestock, Derek) (Entered: 10/25/2023) (10) |
| Oct 24, 2023 | N/A | Remark: MDL panel has been advised. (mkr) (Entered: 10/24/2023) (0) |
| Oct 23, 2023 | 6 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Bayer AG for Bayer Pharma AG filed by Bayer AG and Bayer Pharma AG. (mkr) (Entered: 10/23/2023) (1) |
| Oct 23, 2023 | 7 | Summons Issued as to Cipla Ltd. on 10/23/2023; and Cipla USA Inc. on 10/23/2023. (Attachments: # 1 Summons Issued)(mkr) (Entered: 10/23/2023) (0) |
| Oct 20, 2023 | 1 | Complaint* (1) |
| Oct 20, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mkr) (Entered: 10/23/2023) (3) |
| Oct 20, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: On or about September 6, 2023. Date of Expiration of Patent: January 31, 2039.Thirty Month Stay Deadline: on or about March 6, 2026.(mkr) (Entered: 10/23/2023) (1) |
| Oct 20, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,828,310 B2. (mkr) (Entered: 10/23/2023) (1) |
| Oct 20, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Johnson & Johnson for Janssen Pharmaceuticals, Inc. filed by Janssen Pharmaceuticals, Inc. (mkr) (Entered: 10/23/2023) (1) |
